Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)

Andres Forero-Torres, Jatin Shah, Tina Wood, James Posey, Ronda Carlisle, Catherine Copigneaux, F. Luo, Slawomir Wojtowicz-Praga, Ivor Percent, Mansoor Saleh

Research output: Contribution to journalArticlepeer-review

126 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology